Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an update.
Livzon MABPharm has had its marketing authorization application for Lecankitug Injection, a domestically developed Class 1 therapeutic biological product for adult patients with moderate-to-severe plaque psoriasis, formally accepted for review by China’s National Medical Products Administration. Lecankitug is the first domestically developed and second globally developed dual IL-17A/F inhibitor, and Phase III trial results showed superior efficacy and comparable safety versus secukinumab, positioning Livzon to potentially strengthen its competitiveness in China’s psoriasis treatment market and broaden its innovative biologics portfolio if approval is granted.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group, through its controlling subsidiary Livzon MABPharm, operates in the biopharmaceutical sector with a focus on innovative therapeutic biological products. The company develops monoclonal antibody drugs targeting immune-mediated diseases, aiming to expand its presence in China’s high-value specialty pharmaceuticals market.
Average Trading Volume: 748,300
Technical Sentiment Signal: Hold
Current Market Cap: HK$32.11B
Find detailed analytics on 1513 stock on TipRanks’ Stock Analysis page.